Northwire Canada EditionTuesday, July 14, 2026
Sign inSubscribe
Northwire
⌕
WDO 26.04 −0.9% FVI 11.84 −1.6% OM 1.75 −1.7% ETG 2.99 +0.0% ARTG 31.47 −4.6% LUC 0.163 +1.6% AFM 1.38 +0.0% IMG 20.95 −3.5% CPAU 0.150 +3.5% MMX 0.075 +7.1% IE 12.47 −2.4% SASK 1.09 −1.8% MOG 0.390 +2.6% XIM 0.070 −6.7% S 0.110 −29.0% OMI 0.300 −4.8% WDO 26.04 −0.9% FVI 11.84 −1.6% OM 1.75 −1.7% ETG 2.99 +0.0% ARTG 31.47 −4.6% LUC 0.163 +1.6% AFM 1.38 +0.0% IMG 20.95 −3.5% CPAU 0.150 +3.5% MMX 0.075 +7.1% IE 12.47 −2.4% SASK 1.09 −1.8% MOG 0.390 +2.6% XIM 0.070 −6.7% S 0.110 −29.0% OMI 0.300 −4.8%

Healthcare

Page 52
  1. Mar 05, 2026 · 20:30 · QIPT

    Quipt Home Medical Receives Final Order Approving Arrangement

    Quipt Home Medical Receives Final Order Approving Arrangement

    01
  2. Mar 05, 2026 · 20:06 · RKV

    Rakovina Announces Closing of $1 Million Debenture Unit Private Placement and Debt Settlement Agreements

    Rakovina Announces Closing of $1 Million Debenture Unit Private Placement and Debt Settlement Agreements

    02
  3. Mar 05, 2026 · 18:26 · ADK

    Diagnos to amend convertible debenture, warrant terms

    Diagnos to amend convertible debenture, warrant terms

    03
  4. Mar 05, 2026 · 18:15 · ZYUS

    ZYUS Life Sciences Announces Closing of Debt Financing

    ZYUS Life Sciences Announces Closing of Debt Financing

    04
  5. Mar 05, 2026 · 17:48 · HLS

    HLS Therapeutics launches Nilemdo in Canada

    HLS Therapeutics launches Nilemdo in Canada

    05
  6. Mar 05, 2026 · 17:42 · NURS

    Hydreight invests $300,000 in Insu Therapeutics

    Hydreight invests $300,000 in Insu Therapeutics

    06
  7. Mar 05, 2026 · 17:15 · NLH

    President & CEO Letter to Shareholders

    President & CEO Letter to Shareholders

    07
  8. Mar 05, 2026 · 17:13 · NLH

    Nova Leap Health Corp. Posts Fourth Quarter and Record Full-Year 2025 Revenues and Adjusted EBITDA

    Nova Leap Health Corp. Posts Fourth Quarter and Record Full-Year 2025 Revenues and Adjusted EBITDA

    08
  9. Mar 05, 2026 · 17:10 · CSCI

    COSCIENS Provides Strategic Update

    COSCIENS Provides Strategic Update

    09
  10. Mar 05, 2026 · 17:00 · HELP

    Cybin talks HLP004 phase 2 study results

    Cybin talks HLP004 phase 2 study results

    10
  11. Mar 05, 2026 · 16:05 · PRN

    Profound Medical Reports Fourth Quarter and Full Year 2025 Financial Results

    Profound Medical Reports Fourth Quarter and Full Year 2025 Financial Results

    11
  12. Mar 05, 2026 · 15:45 · ADK

    DIAGNOS Announces Amendments to Convertible Debentures and Stock Warrants

    DIAGNOS Announces Amendments to Convertible Debentures and Stock Warrants

    12
  13. Mar 05, 2026 · 08:00 · NURS

    Hydreight Technologies Inc. Announces Strategic Investment in Insu Therapeutics to Advance Needle-Free Peptide Delivery Technology

    Hydreight Technologies Inc. Announces Strategic Investment in Insu Therapeutics to Advance Needle-Free Peptide Delivery Technology

    13
  14. Mar 05, 2026 · 07:30 · HELP

    Helus Pharma Announces Topline Results in Phase 2 Signal Detection Study for HLP004 in Patients with Generalized Anxiety Disorder

    Helus Pharma Announces Topline Results in Phase 2 Signal Detection Study for HLP004 in Patients with Generalized Anxiety Disorder

    14
← Newer Older →